Form 4 for ALT Altimmune, Inc.
Accepted 2024-02-01 00:00:00 ET · period of report 2024-01-30 · accession 0001104659-24-009543 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-02-01 | 2024-01-30 | ALT | Roberts M Scot | CSO | F - Tax | $9.80 | -2,709 | 27.0K | -9% | -$26.5K |
| D | 2024-02-01 | 2024-01-31 | ALT | Roberts M Scot | CSO | A - Grant | $2.69 | +5,860 | 32.9K | +22% | +$15.8K |
| D | 2024-02-01 | 2024-01-30 | ALT | Roberts M Scot | CSO | M - OptEx | $0.00 | +9,275 | 29.7K | +45% | $0 |
| D | 2024-02-01 | 2024-01-30 | ALT | Roberts M Scot | CSO | M - OptEx | $0.00 | -9,275 | 27.8K | -25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, par value $0.0001 | 2024-01-30 | F | D | 2,709 | $9.80 | 26,990 | D | — | — | |
| 2 | Common | Common Stock, par value $0.0001 | 2024-01-31 | A | A | 5,860 | $2.69 | 32,850 | D | — | — | (F4) In accordance with the ESPP, these shares were purchased based on 85% of the opening price of the issuer's common stock on August 1, 2023. |
| 3 | Common | Common Stock, par value $0.0001 | 2024-01-30 | M | A | 9,275 | $0.00 | 29,699 | D | — | — | (F1) Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. |
| 4 | Derivative | Restricted Stock Units | 2024-01-30 | M | D | 9,275 | $0.00 | 27,825 | D | — · — to — | 9,275 Common Stock, par value $0.0001 | (F1) Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. (F5) The RSUs become vested in substantially equal annual installments over the 4 years following January 30, 2023, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. |